Scholarlink

<p>Sickle cell disease (SCD) is a debilitating genetic disorder of the red blood cells. In severe cases, it may lead to pain, hospitalization, stroke, heart disease, organ damage, acute chest syndrome caused by blockages in the lungs, and chronic complications which may affect the kidneys, lungs, joints, and eyes. In the United States (US), about 100,000 people have SCD, with 90% being African American. Although the US Food and Drug Administration’s recently approved groundbreaking base editing gene therapies of Casgevy and Lyfgenia have been declared promising in treating SCD, uptake for the therapies has been low. Though the treatment of SCD through gene therapy has sparked some excitement in the African American community, it is also causing a dilemma and challenges. This paper documents the dilemma and challenges associated with gene therapy among the African American SCD community and what can be done to address them.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Sickle Cell Disease and Gene Therapy Among African Americans: A Dilemma and Challenge

  • 期刊论文

  • 发表日期：

    2025年10月20日

查看全文
  • Elizabeth Armstrong-Mensah,
  • Ato Kwamena Tetteh,
  • Emmanuel Ofori,
  • David Armstrong-Mensah

摘要

Sickle cell disease (SCD) is a debilitating genetic disorder of the red blood cells. In severe cases, it may lead to pain, hospitalization, stroke, heart disease, organ damage, acute chest syndrome caused by blockages in the lungs, and chronic complications which may affect the kidneys, lungs, joints, and eyes. In the United States (US), about 100,000 people have SCD, with 90% being African American. Although the US Food and Drug Administration’s recently approved groundbreaking base editing gene therapies of Casgevy and Lyfgenia have been declared promising in treating SCD, uptake for the therapies has been low. Though the treatment of SCD through gene therapy has sparked some excitement in the African American community, it is also causing a dilemma and challenges. This paper documents the dilemma and challenges associated with gene therapy among the African American SCD community and what can be done to address them.